Key Structural and Operational Considerations for Biosimilar Adoption

Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

Now Viewing

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

EP: 6.Positioning Biosimilars in Clinical Practice

EP: 7.Assessing Patient Confidence With Biosimilars

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

EP: 9.The Growing Market for Biosimilars

EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models

EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies

EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability

EP: 13.How the IRA is Reshaping Biosimilar Adoption

EP: 14.Cost Savings Potential Associated With the Use of Biosimilars

EP: 15.Examining the Role of Interchangeability in Clinical Practice

EP: 16.Optimizing the Implementation of Biosimilars Into Formularies

EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars

EP: 18.Working With Policy Makers to Effectively Implement Biosimilars

Video content above is prompted by the following:

• When health care systems move to biosimilar adoption, what are the key structural and operational considerations that go into this transition?

Related Videos

Related Content

Advertisement

July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 30th 2025

Prolonged ED Stays, Boarding Times Among Older Adults Underscore Systemic Hospital Strain

Brooke McCormick

The recent increase in prolonged emergency department (ED) stays and boarding times for older adults reveals systemic challenges in US hospital care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

Related Content

Advertisement

July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 30th 2025

Prolonged ED Stays, Boarding Times Among Older Adults Underscore Systemic Hospital Strain

Brooke McCormick

The recent increase in prolonged emergency department (ED) stays and boarding times for older adults reveals systemic challenges in US hospital care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.